ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)
Provided By GlobeNewswire
Last update: Aug 13, 2025
$15.7 million in revenue, including $12.8 million in neffy U.S. net product revenue in second quarter of 2025
Growth for neffy in the U.S. driven by increased payor access with additional near-term growth anticipated from national direct-to-consumer (DTC) campaign and pediatric co-promote partnership
Read more at globenewswire.com
